UBS Group
MDXH icon

UBS Group’s MDxHealth MDXH Stock Holding History

UBS Group’s Portfolio MDXH Stock Details MDXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Sell
3
-173
-98% -$232 ﹤0.01% 10387
2026
Q1 		$405 Sell
176
-1,513
-90% -$5.14K ﹤0.01% 9916
2025
Q4 		$6.03K Sell
1,689
-518
-23% -$2.05K ﹤0.01% 8593
2025
Q3 		$10.3K Buy
2,207
+737
+50% +$2.27K ﹤0.01% 8552
2025
Q2 		$3.25K Hold
1,470
– – ﹤0.01% 9373
2025
Q1 		$2.09K Sell
1,470
-28
-2% -$51 ﹤0.01% 9395
2024
Q4 		$3.55K Buy
1,498
+28
+2% +$57 ﹤0.01% 8856
2024
Q3 		$3.06K Hold
1,470
– – ﹤0.01% 8318
2024
Q2 		$3.51K Sell
1,470
-133
-8% -$357 ﹤0.01% 8204
2024
Q1 		$4.15K Buy
+1,603
New +$5.62K ﹤0.01% 7649
2023
Q3 		– Sell
-100
Closed -$341 – 9767
2023
Q2 		$341 Buy
+100
New +$366 ﹤0.01% 8290
2023
Q1 		– Sell
-2,644
Closed -$17.5K – 10043
2022
Q4 		$17.5K Buy
2,644
+451
+21% +$3.2K ﹤0.01% 7830
2022
Q3 		$15K Buy
2,193
+2
+0.1% +$15 ﹤0.01% 7811
2022
Q2 		$18K Buy
2,191
+1,886
+618% +$14.6K ﹤0.01% 7017
2022
Q1 		$3K Buy
+305
New +$2.64K ﹤0.01% 9461

Other funds holding MDXH

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

UBS Group's MDXH Position: Q2 2026 in Review

UBS Group reduced its MDxHealth (MDXH) stake by 98% in Q2 2026, selling an estimated $232 and leaving 3 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #10387.

UBS Group first reported a position in MDXH in Q1 2022 and has held it in 15 quarters since. The position peaked at $18K in Q2 2022. 26 funds tracked by Wall St. Rank hold MDXH as of Q2 2026.

  • UBS Group held 3 shares of MDxHealth worth $1 as of Q2 2026.
  • UBS Group sold 173 MDxHealth shares in Q2 2026, an estimated $232.
  • MDxHealth made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10387 holding.
  • UBS Group first reported a position in MDxHealth in Q1 2022 and has held it in 15 quarters since.
  • UBS Group's MDxHealth position peaked at $18K in Q2 2022.
  • 26 funds tracked by Wall St. Rank held MDxHealth as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.